MX2023015469A - Metodos y composiciones para estimular la actividad inmunitaria. - Google Patents
Metodos y composiciones para estimular la actividad inmunitaria.Info
- Publication number
- MX2023015469A MX2023015469A MX2023015469A MX2023015469A MX2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A MX 2023015469 A MX2023015469 A MX 2023015469A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- compositions
- methods
- binds
- binding domain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902832A AU2021902832A0 (en) | 2021-09-01 | Methods and compositions for stimulating immune activity | |
| PCT/AU2022/051070 WO2023028657A1 (en) | 2021-09-01 | 2022-09-01 | Methods and compositions for stimulating immune activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015469A true MX2023015469A (es) | 2024-01-19 |
Family
ID=85410590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015469A MX2023015469A (es) | 2021-09-01 | 2022-09-01 | Metodos y composiciones para estimular la actividad inmunitaria. |
| MX2023015028A MX2023015028A (es) | 2021-09-01 | 2022-09-01 | Nuevos aglutinantes del p2x7 disfuncional. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015028A MX2023015028A (es) | 2021-09-01 | 2022-09-01 | Nuevos aglutinantes del p2x7 disfuncional. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240368282A1 (enExample) |
| EP (2) | EP4395813A4 (enExample) |
| JP (2) | JP2024532482A (enExample) |
| CN (2) | CN117881421A (enExample) |
| AU (2) | AU2022335932A1 (enExample) |
| CA (2) | CA3223079A1 (enExample) |
| MX (2) | MX2023015469A (enExample) |
| WO (2) | WO2023028657A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3240805T3 (fi) * | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| US20220267450A1 (en) * | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| AU2024232401A1 (en) * | 2023-03-08 | 2025-08-21 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors for binding to dysfunctional p2x 7 receptor |
| WO2024211413A2 (en) * | 2023-04-05 | 2024-10-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Trogocytosis in cancer cells and methods for treating cancer related thereto |
| WO2024220870A1 (en) * | 2023-04-19 | 2024-10-24 | The University Of Chicago | Antibody-targeted enzymatic chemoprotection |
| AU2024269870A1 (en) * | 2023-05-05 | 2025-11-20 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| EP4735479A1 (en) * | 2023-06-30 | 2026-05-06 | Biosceptre (Aust) Pty Ltd | Molecules and methods for activating car t cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2467404B1 (en) * | 2009-08-20 | 2015-09-30 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
| WO2011075789A1 (en) * | 2009-12-24 | 2011-06-30 | Biosceptre International Limited | Antibodies to non-functional oligomeric p2x7 receptors |
| US20180037650A1 (en) * | 2015-04-02 | 2018-02-08 | Biosceptre (Uk) Limited | Pain Treatment |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| MX2019004410A (es) * | 2016-10-21 | 2019-09-26 | Biosceptre Uk Ltd | Particulas citotoxicas. |
| CN112166193A (zh) * | 2018-05-21 | 2021-01-01 | 生物权威（英国）有限公司 | 具有经修饰的接头结构域的嵌合抗原受体及其用途 |
| US20220177583A1 (en) * | 2019-03-20 | 2022-06-09 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| CN113853388B (zh) * | 2019-03-27 | 2024-07-19 | 加拿大国家研究委员会 | 抗-egfrviii抗体及其抗原结合片段 |
| EP4304610A4 (en) * | 2021-03-11 | 2025-03-05 | Biosceptre (Aust) Pty Ltd | Novel cell therapy system |
-
2022
- 2022-09-01 US US18/688,086 patent/US20240368282A1/en active Pending
- 2022-09-01 EP EP22862427.6A patent/EP4395813A4/en active Pending
- 2022-09-01 MX MX2023015469A patent/MX2023015469A/es unknown
- 2022-09-01 US US18/686,554 patent/US20240376193A1/en active Pending
- 2022-09-01 CA CA3223079A patent/CA3223079A1/en active Pending
- 2022-09-01 WO PCT/AU2022/051070 patent/WO2023028657A1/en not_active Ceased
- 2022-09-01 WO PCT/AU2022/051066 patent/WO2023028653A1/en not_active Ceased
- 2022-09-01 JP JP2024513926A patent/JP2024532482A/ja active Pending
- 2022-09-01 AU AU2022335932A patent/AU2022335932A1/en active Pending
- 2022-09-01 JP JP2024513973A patent/JP2024532489A/ja active Pending
- 2022-09-01 CA CA3223086A patent/CA3223086A1/en active Pending
- 2022-09-01 CN CN202280059679.4A patent/CN117881421A/zh active Pending
- 2022-09-01 EP EP22862431.8A patent/EP4395814A4/en active Pending
- 2022-09-01 MX MX2023015028A patent/MX2023015028A/es unknown
- 2022-09-01 AU AU2022341030A patent/AU2022341030A1/en active Pending
- 2022-09-01 CN CN202280053364.9A patent/CN117813109A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3223079A1 (en) | 2023-03-09 |
| WO2023028657A1 (en) | 2023-03-09 |
| AU2022335932A1 (en) | 2023-11-30 |
| JP2024532482A (ja) | 2024-09-05 |
| JP2024532489A (ja) | 2024-09-05 |
| CN117813109A (zh) | 2024-04-02 |
| EP4395814A1 (en) | 2024-07-10 |
| CA3223086A1 (en) | 2023-03-09 |
| CN117881421A (zh) | 2024-04-12 |
| US20240368282A1 (en) | 2024-11-07 |
| AU2022341030A1 (en) | 2023-11-30 |
| MX2023015028A (es) | 2024-02-16 |
| EP4395813A1 (en) | 2024-07-10 |
| EP4395813A4 (en) | 2025-07-09 |
| WO2023028653A1 (en) | 2023-03-09 |
| US20240376193A1 (en) | 2024-11-14 |
| EP4395814A4 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023015469A (es) | Metodos y composiciones para estimular la actividad inmunitaria. | |
| JOP20210289A1 (ar) | مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها | |
| IL311603B1 (en) | Bispecific antibodies and compounds containing them for cancer treatment | |
| WO2021227307A8 (zh) | 抗cd73抗体及其用途 | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
| BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
| MX2022003005A (es) | Composiciones y metodos de anticuerpos anti-cd39. | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
| MX2022013876A (es) | Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos. | |
| BR112022024501A2 (pt) | Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| BR112022018254A2 (pt) | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo | |
| MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
| EA202092518A1 (ru) | Композиции и способы лечения рака | |
| WO2023201234A3 (en) | Anti-variable muc1* antibodies and uses thereof | |
| MX2022011050A (es) | Anticuerpos anti-cd36 y su uso para tratar cancer. | |
| EA202192757A1 (ru) | Способ лечения опухолей | |
| BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo | |
| WO2021003050A3 (en) | Cd38-binding agents and uses thereof |